Clinical Obesity

Clinical Obesity is the official clinical journal of the World Obesity Federation, published by Wiley and issued six times a year, carrying translational and clinical research on obesity and its co-morbidities, with a 2025 Journal Impact Factor of 2.4 and a CiteScore of 4.《临床肥胖》是世界肥胖联盟（World Obesity Federation）的官方临床期刊，由 Wiley 出版，每年 6 期，刊载肥胖及其共病的转化研究与临床研究，2025 年期刊影响因子为 2.4，CiteScore 为 4。

Scope

• The stated remit is high quality translational and clinical research, together with reviews, on obesity and its co-morbidities, written for an international readership of clinicians and investigators.官方宗旨是发表肥胖及其共病方面的高质量转化研究与临床研究以及综述，读者面向国际范围的临床医生与研究者。
• A qualifying clause narrows that remit. Submissions must show immediate relevance to the treatment of patients and to the understanding of human obesity.一条限定语把范围收窄，稿件须与患者治疗以及对人肥胖的理解有直接关联。
• Ten subject areas are named. The first covers patient assessment, classification, diagnosis and prognosis, which places clinical characterisation of the individual patient at the head of the list.宗旨点明十个主题方向。第一组是患者评估、分类、诊断与预后，把对个体患者的临床刻画放在首位。
• Pharmacological treatment, clinical trials and the supporting studies behind them form the second area, and this is the part of the remit where drug development meets trial evidence.药物治疗、临床试验与支撑这类试验的研究构成第二组，药物研发与试验证据在这一方向上交汇。
• Bariatric surgery and the follow-up it requires are named, and so are operative procedures that remove body fat, which keeps surgical care inside the clinical remit.减重手术与随之而来的随访被单列，切除体脂的外科手段同样在列，两类内容把外科治疗留在临床范围之内。
• Weight loss through drugs, diet and behavioural approaches is a further area, and clinical physiology gives the journal a route into how excess adiposity acts on the body.通过药物、饮食与行为途径减重是另一个方向，临床生理学则为刊物提供了理解过剩脂肪如何作用于身体的入口。
• Clinically relevant epidemiology belongs on the list, yet papers reporting regional or local prevalence data are refused unless they are tied to new clinical findings.具临床相关性的流行病学也在名单之内，只报区域或局地患病率数据的稿件不予接受，除非与新的临床发现挂钩。
• The psychological aspects of obesity and its co-morbidities are named, and nursing care of patients with obesity closes the ten areas as a subject in its own right.肥胖及其共病的心理层面被点名，肥胖患者的护理则作为独立主题为十个方向收尾。
• Policy, practice and ethics are described as part of the conversation the journal hosts, so the title carries argument as well as data.政策、实践与伦理被写进刊物主持的讨论，内容因此不止于数据，也容纳论证。
• Readers are named at length, from endocrinology, cardiology, gastroenterology and nutrition through paediatrics, obstetrics and rheumatology to bariatric surgery, internal medicine and general practice.读者名单写得很细，从内分泌、心血管、消化与营养，经儿科、产科与风湿，一直排到减重外科、内科与全科。
• Original Research carries a ceiling of 5,000 words, 50 references and 6 tables and figures, and the count excludes the cover page, abstract, references, tables and figures.原创研究的限额是 5000 词，50 条参考文献，图表合计 6 个，字数不计封面页与摘要，也不计参考文献与表图。
• A Review Article may run to 6,000 words, 60 references and 6 tables and figures. Unsolicited narrative reviews are welcome, though a proposal with an abstract and outline should reach the editors first.综述上限为 6000 词，60 条参考文献，图表 6 个；非邀稿的叙述性综述可以投，但宜先把摘要与提纲送编辑过目。
• Commentary and Editorial hold to 2,000 words, 10 references and no tables or figures, and most commentaries are commissioned even though unsolicited ones are read.评论与社论的上限是 2000 词，10 条参考文献，不收图表，多数评论按约稿处理，非邀稿同样会读。
• Correspondence is capped at 1,000 words, 5 references and 1 table or figure, and it must raise a factual error or substantive disagreement, with a reply from the original first author.通讯稿上限 1000 词，5 条参考文献，图表 1 个，须针对已发表文章提出事实错误或重大分歧，原文第一作者会作回应。
• Case Reports allow 2,500 words, 10 references and 3 tables or figures, and only genuinely rare cases that add insight into pathogenesis, complications, investigation or treatment are taken.病例报告的上限是 2500 词，10 条参考文献，图表 3 个，只收真正罕见且对发病机制、并发症、检查或治疗有新见解的病例。
• Original research opens with the two boxes headed What is already known about this subject and What this study adds, each holding at most three short sentences, followed by an abstract of about 200 words and references in AMA style.原创稿的开头是两栏，一栏为「What is already known about this subject」，另一栏为「What this study adds」，各至多 3 条短句，随后是约 200 词的摘要，参考文献用 AMA 样式。

History

• The launch editorial, titled 'Clinical Obesity – a new journal for a new clinical era', went online on 22 October 2010, ahead of the first issue.创刊社论「Clinical Obesity – a new journal for a new clinical era」于 2010 年 10 月 22 日先行在线，早于首期出版。
• Volume 1, issue 1 followed in February 2011, which fixes the founding year at 2011, the date the National Library of Medicine also records.第 1 卷第 1 期随后于 2011 年 2 月出版，创刊年因此定为 2011 年，美国国家医学图书馆的记录同样以此为起点。
• One volume has covered a calendar year ever since, so the 2026 volume is the sixteenth, and the numbering has not broken since the launch.此后每年一卷，2026 年为第 16 卷，卷号自创刊起没有中断。
• Six issues make up a volume. On the 2026 volume the visible issues 3 to 6 are dated June, August, October and December, a bimonthly rhythm rather than a monthly one.每卷 6 期，2026 年第 16 卷可见的第 3 至第 6 期分别标于 6 月、8 月、10 月与 12 月，节奏为双月刊而非月刊。
• Wiley holds the imprint, while the copyright line credits the World Obesity Federation, a split that also shows in the two separate offices behind the title.出版方为 Wiley，版权行归于世界肥胖联盟，两个分设的办公室也体现着这一格局。
• Emerging Sources Citation Index is the Clarivate database that carries the title, so the journal is an ESCI entry rather than a Science Citation Index Expanded one.该刊在 Clarivate 的收录库为 Emerging Sources Citation Index，属 ESCI，不在 Science Citation Index Expanded 之列。
• That placement sets the terms of the ranking. Journal Citation Reports puts the title at 135 of 198 in endocrinology and metabolism, a Q3 position inside the ESCI edition.收录库决定了排名口径，期刊引证报告把它排在内分泌与代谢类目 198 种刊物的第 135 位，为 ESCI 版次中的 Q3。
• The 2025 Journal Impact Factor is 2.4 and the five-year figure is 2.6, while Scopus gives the title a CiteScore of 4.2025 年期刊影响因子为 2.4，五年影响因子为 2.6，Scopus 给出的 CiteScore 为 4。
• Recent impact factors read 2.2 for 2023, 2.1 for 2024 and 2.4 for 2025, a line that has stayed flat rather than climbed.近三年影响因子为 2023 年 2.2，2024 年 2.1，2025 年 2.4，走势平缓。
• Publisher statistics put the acceptance rate at 16 per cent, and the median time from submission to a first decision at 9 days.出版方统计的录用率为 16%，从投稿到首次决定的中位时间为 9 天。
• Output runs at about 51 articles a year, total citations reach 1740, and the cited half-life is 5.8 years.年发文约 51 篇，总被引 1740 次，被引半衰期为 5.8 年。
• Gold open access takes 53.23 per cent of the content, which makes the title hybrid, with OnlineOpen open to authors who need immediate access for a funder.金色开放获取占全部内容的 53.23%，刊物因此走混合路线，需要满足资助方即时开放要求的作者可选 OnlineOpen。
• Funders with a public access mandate are served by that route, and the Wellcome Trust and RCUK policies are named as the ones that allow CC-BY.有开放获取要求的资助方可以走这条路径，Wellcome Trust 与 RCUK 的政策被点名为允许 CC-BY 的两家。

Editors

• Shahrad Taheri holds the editor-in-chief post. He is professor of medicine at Weill Cornell Medicine-Qatar in Doha, where he also directs the clinical research core.主编为 Shahrad Taheri，在卡塔尔多哈的 Weill Cornell Medicine-Qatar 任医学教授，并主管该校的临床研究核心。
• Two associate editors share the load. Nitin Kapoor works on endocrinology and diabetes at Christian Medical College in Vellore, India, and Ming Ming Teh on endocrinology at Singapore General Hospital.两位副编辑分担稿件，Nitin Kapoor 在印度 Vellore 的 Christian Medical College 研究内分泌与糖尿病，Ming Ming Teh 在新加坡中央医院（Singapore General Hospital）从事内分泌工作。
• The editorial office runs from the federation in London, with Ellie Needs as the contact, while production sits with an editor at Wiley.编辑部由伦敦的世界肥胖联盟承担，联系人为 Ellie Needs，制作环节由 Wiley 的编辑对接。
• Twenty-seven people sit on the editorial board, drawn from North America, Europe, South America, Asia and Oceania, and the list mixes university departments with hospital clinics that treat patients.编委共 27 人，覆盖北美、欧洲与南美，也含亚洲与大洋洲，名单里既有大学院系，也有接诊患者的医院科室。
• The spread is wide. David B. Allison works at Indiana University, Arya M. Sharma at the University of Alberta, Priya Sumithran at Austin Health in Melbourne and Mandy Ho at the University of Hong Kong.分布很广，David B. Allison 在 Indiana University，Arya M. Sharma 在 University of Alberta，Priya Sumithran 在墨尔本的 Austin Health，Mandy Ho 在香港大学。
• Review is described as stringent. Manuscripts go to the editors, to board members or to outside experts, and the responsible editor issues the decision through ScholarOne.评审被形容为严格，稿件交由编辑、编委或外部专家评阅，决定由负责该稿的编辑通过 ScholarOne 发出。
• Editors may return a paper without full review when it lacks competitiveness or falls outside the interests of the readership.稿件缺乏竞争力或超出读者兴趣时，编辑可以不经完整外审直接退稿。
• Acceptance turns on priority as much as on technical quality, since every paper is weighed against the submissions then under consideration.录用与否既看技术质量也看发表优先级，每篇稿件都与当时在审的其它稿件放在一起比较。
• Appeals against rejection are not entertained, and rejected work is generally not accepted again, a stance the guide states without hedging.刊物不受理对拒稿的申辩，被拒稿件一般也不再接受，指南把这层意思写得很直白。
• Submissions enter through ScholarOne, and the corresponding author must supply an ORCID iD before a file can proceed.稿件经 ScholarOne 提交，通讯作者须提供 ORCID iD，否则流程无法推进。
• The journal is a COPE member, screens every submission for overlap with published work, and asks authors to follow CONSORT, STROBE or PRISMA as the design requires.刊物是 COPE 成员，对每篇稿件做与已发表作品的比对，并要求作者依研究设计选用 CONSORT 与 STROBE 等报告规范，系统性综述另循 PRISMA。
• A data availability statement is required, preprints posted on a server may be sent for review, and declined papers can be offered transfer to another Wiley title.稿件须附数据可及性声明，已上预印本服务器的稿件可以送审，未录用稿可被推荐转投其它 Wiley 期刊。